Palantir ( PLTR) is known for its AI-powered platforms in defence and intelligence, but it has been making significant moves in the commercial sector as well. The company's expansion into this space, ...

The tech-driven advisor platform provider has also added RIAs representing $400M to its growing stable of affiliates.

With the announcement that the great David Lynch died on January 16, the world hasn’t just lost one of its greatest filmmakers: It’s lost one of its greatest artists, period. The work of a ...

Good day and welcome to the Stifel Financial fourth quarter financial results conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr ...

Stifel noted that Reuters reported this morning that Japan’s NEC is considering making a bid for CSG Systems (CSGS) and that talks between the two are in “early stages.” NEC owns Netcracker ...

(RTTNews) - Stifel Financial Corp. (SF) revealed earnings for its fourth quarter that increased from last year and beat the Street estimates. The company's earnings totaled $234.69 million ...

Stifel Financial Corp. announced a cash dividend of $0.46 per share on its common stock, payable on March 17, 2025, to shareholders recorded by March 3, 2025. Additionally, the company declared ...

2025 Baseball Hall of Fame inductee Ichiro Suzuki is one of the most fascinating characters in MLB history, and Alex Rodriguez confirmed a fun story that adds to his lore. As part of a career ...

(Photo by DAVID GRAY / AFP) “That match up for Alex is not a good one. “It’s tough for us to break down how he can eventually beat this guy. He’s not winning sets off him. “So as good as ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

Shares of Edgewise Therapeutics (NASDAQ:EWTX) traded flat on Wednesday after Stifel launched its coverage with a Hold recommendation, indicating a balanced risk-reward profile for the muscle drug ...